Activation of Pyroptotic Cell Death Pathways in Cancer: An Alternative Therapeutic Approach

Kanipandian Nagarajan1, Kannan Soundarapandian2, Rick F Thorne3

  • 1Department of Hepato-Biliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan Province, People's Republic of China.

Insights

Pyroptosis, a programmed cell death pathway activated by Caspase-1, offers a novel approach to cancer treatment. Understanding its role in cancer cell death could lead to new therapeutic strategies.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunology

Background:

  • Cancer develops from genetic variations causing uncontrolled cell growth and evasion of cell death.
  • While apoptosis, autophagy, and necrosis are known cell death pathways, cancer treatment remains challenging.
  • Pyroptosis is a distinct programmed cell death form, primarily triggered by Caspase-1, involving cell swelling and lysis.

Purpose of the Study:

  • To review recent advancements in understanding pyroptosis.
  • To explore the emerging role of pyroptosis in promoting cancer cell death.

Main Methods:

  • Literature review of studies on pyroptosis and cancer.
  • Analysis of molecular mechanisms underlying Caspase-1 activation in tumors.

Main Results:

  • Pyroptosis is initiated by specific death signals leading to cytokine release, cell swelling, and bursting.
  • Caspase-1 deficiency can promote tumor progression through inflammation.
  • The precise mechanisms of Caspase-1 activation in tumor tissues require further investigation.

Conclusions:

  • Pyroptosis presents a promising avenue for cancer therapy by inducing cancer cell death.
  • Further research into pyroptosis mechanisms, particularly Caspase-1 activation in tumors, is crucial for therapeutic development.

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
181
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
178
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
160
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
9.6K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.4K
C4 Pathway and CAM01:27

C4 Pathway and CAM

Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
48.9K